No efficacy data yet. Actinogen has initiated the open-label extension of its XanaMIA pivotal program in Alzheimer’s disease, dosing the first participant after completing 36 weeks in the randomized phase. The core trial enrolls 247 patients with mild to moderate disease on Xanamem 10 mg once daily or placebo for 36 weeks; the extension offers up to 25 months of active drug to all completers. An independent data monitoring committee cleared the study on safety and futility in January, and final topline data from the randomized phase are expected in November 2026.
The move formalizes a two-track development plan: complete the 36-week randomized readout while accumulating longer-term safety and observational effectiveness data on measures including CDR-SB, cognition, and activities of daily living. Actinogen plans progressive analyses from the extension, benchmarking outcomes against historical controls and the placebo-controlled data set. The company has also signaled intent to engage regulators on accelerated pathways and to leverage recent FDA guidance that, in defined circumstances, allows approval based on a single pivotal trial with adequate supporting evidence, while it opens a parallel dialogue with EMA on a streamlined EU route.
Strategically, the extension is a hedge against the inherent constraints of a sub-12-month randomized window in Alzheimer’s, where regulators and payers increasingly prioritize durability and functional impact. It also sharpens the positioning of Xanamem, an oral 11β-HSD1 inhibitor targeting brain cortisol regulation, as a non-amyloid alternative that avoids serial MRI safety monitoring and infusion infrastructure. The trade-off is evidentiary: observational extension data using historical comparators rarely carry the inferential weight of a concurrent control, and any accelerated filing predicated on a single pivotal will face scrutiny on internal consistency across endpoints, sustained effect beyond 36 weeks, and alignment with clinically meaningful functional outcomes. The depression program remains a secondary vector; publication of Phase 2a results is pending, but further investment there appears contingent on the Alzheimer’s signal.
For sites, the extension may simplify logistics relative to antibody programs by eliminating infusion scheduling and routine ARIA surveillance, yet it introduces a different operational burden: extended retention, rater drift management over multi-year follow-up, and tighter control of missing data in cognition and function assessments. CROs and data vendors should anticipate expanded central rating, adjudication, and longitudinal data quality plans, with emphasis on ensuring comparability between the randomized and extension phases. Sponsors watching the space will note the template: pair a shorter placebo-controlled study with an immediate extension to build a totality-of-evidence package while preserving participant continuity and minimizing attrition.
The next inflection arrives with November’s topline. Signals to watch include the magnitude and consistency of separation on CDR-SB at 36 weeks, concordance with cognitive and ADL measures, and any subgroup effects between mild and moderate populations. From the extension, the slope of decline versus historical progression rates and the long-term safety profile will determine whether the observational data can credibly support discussions on accelerated pathways. Regulators will likely expect either a second confirmatory study or robust, prospectively defined supportive evidence if a single-pivotal strategy is pursued, particularly in a heterogeneous disease area with high variability. Operationally, Actinogen will need to show it can sustain retention through 25 months, maintain rater calibration across geographies, and preempt data gaps that could dilute effect estimates. If the randomized readout is positive and the extension corroborates durability, expect a clearer view of the regulatory plan and the resourcing required for a confirmatory program in parallel with approval efforts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
